Search Results
Search for other papers by Sayaka Akieda-Asai in
Google Scholar
PubMed
Search for other papers by Paul-Emile Poleni in
Google Scholar
PubMed
Search for other papers by Kazuya Hasegawa in
Google Scholar
PubMed
Search for other papers by Yukari Date in
Google Scholar
PubMed
( Bjorbaek & Kahn 2004 ). Leptin also inhibits AMP-activated protein kinase (AMPK) activity in the arcuate nucleus and in the paraventricular nucleus of the hypothalamus ( Minokoshi et al . 2004 ). Glucagon-like peptide-1 (GLP1), a gastrointestinal hormone
Department of Physiology, University of Toronto, Toronto, ON, Canada
Search for other papers by Paige V Bauer in
Google Scholar
PubMed
Search for other papers by Frank A Duca in
Google Scholar
PubMed
. 2015 , Buse et al . 2016 ). Interestingly, this is not the only evidence for a therapeutic role of the gut in diabetes treatment. Over the past decade, incretin-based therapies including glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl
Search for other papers by Weiwei Xu in
Google Scholar
PubMed
Search for other papers by Jamie Morford in
Google Scholar
PubMed
Search for other papers by Franck Mauvais-Jarvis in
Google Scholar
PubMed
induces intra-islet glucagon-like peptide-1 (GLP-1) production and enhances beta cell survival . Diabetologia 54 2067 – 2076 . ( https://doi.org/10.1007/s00125-011-2181-x ) 10.1007/s00125-011-2181-x 21567300 Lubahn DB Joseph DR Sullivan PM Willard
Search for other papers by Alessandro Pocai in
Google Scholar
PubMed
insulin. Recent work on understanding the physiological function of proglucagon-derived peptides has renewed interest in glucagon-based therapeutics. One of these peptides is glucagon-like peptide-1 (GLP1), which is secreted from the L cells of the
Search for other papers by Neerav Mullur in
Google Scholar
PubMed
Search for other papers by Arianne Morissette in
Google Scholar
PubMed
Department of Biochemistry, Microbiology and Immunology, The University of Ottawa, Faculty of Medicine, Ottawa, Ontario, Canada
Search for other papers by Nadya M Morrow in
Google Scholar
PubMed
Department of Biochemistry, Microbiology and Immunology, The University of Ottawa, Faculty of Medicine, Ottawa, Ontario, Canada
Search for other papers by Erin E Mulvihill in
Google Scholar
PubMed
administration ( McIntyre et al. 1965 ). The incretin hormones, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1) potentiate meal-stimulated insulin secretion through direct and indirect actions on islet β-cells. The first
Search for other papers by Tetsuhiro Kakimoto in
Google Scholar
PubMed
Search for other papers by Hirotaka Kimata in
Google Scholar
PubMed
Search for other papers by Satoshi Iwasaki in
Google Scholar
PubMed
Search for other papers by Atsushi Fukunari in
Google Scholar
PubMed
Search for other papers by Hiroyuki Utsumi in
Google Scholar
PubMed
, Yoon et al . 2003 ), suggesting that subjects with insulin resistance develop diabetes with the onset of β-cell dysfunction. Drugs to effectively increase insulin-secreting β-cells have been long-awaited. Glucagon-like peptide-1 (GLP-1), a member of
Search for other papers by Sehee Kim in
Google Scholar
PubMed
Search for other papers by Minho Moon in
Google Scholar
PubMed
Search for other papers by Seungjoon Park in
Google Scholar
PubMed
pharmacological intervention of MMP-3 and microglial activation could be considered as plausible candidates for neuroprotective agents in PD. Glucagon-like peptide-1 (GLP-1), an endogenous 30-amino acid gut–brain peptide hormone, is synthesized from proglucagon
Search for other papers by Qiaoli Cui in
Google Scholar
PubMed
Search for other papers by Yijing Liao in
Google Scholar
PubMed
Search for other papers by Yaojing Jiang in
Google Scholar
PubMed
Search for other papers by Xiaohang Huang in
Google Scholar
PubMed
Search for other papers by Weihong Tao in
Google Scholar
PubMed
Search for other papers by Quanquan Zhou in
Google Scholar
PubMed
Search for other papers by Anna Shao in
Google Scholar
PubMed
Search for other papers by Ying Zhao in
Google Scholar
PubMed
Search for other papers by Jia Li in
Google Scholar
PubMed
Search for other papers by Anran Ma in
Google Scholar
PubMed
Search for other papers by Zhihong Wang in
Google Scholar
PubMed
Search for other papers by Li Zhang in
Google Scholar
PubMed
Search for other papers by Zunyuan Yang in
Google Scholar
PubMed
Search for other papers by Yinan Liang in
Google Scholar
PubMed
Search for other papers by Minglin Wu in
Google Scholar
PubMed
Search for other papers by Zhenyan Yang in
Google Scholar
PubMed
Search for other papers by Wen Zeng in
Google Scholar
PubMed
Shanghai Yinuo Pharmaceutical Co., Ltd., Shanghai, China
Keenan Research Centre for Biomedical Science, Division of Endocrinology and Metabolism, St. Michael’s Hospital, Toronto, Ontario, Canada
Search for other papers by Qinghua Wang in
Google Scholar
PubMed
Introduction Glucagon-like peptide 1 (GLP-1) is an incretin hormone produced and secreted by intestinal L cells in response to nutrients ingestion. GLP-1 regulates glucose metabolism mainly by stimulating postprandial insulin secretion and
Search for other papers by Benjamin J Lamont in
Google Scholar
PubMed
Search for other papers by Sofianos Andrikopoulos in
Google Scholar
PubMed
Introduction The incretins glucagon-like peptide 1 (GLP1) and glucose-dependent insulinotropic polypeptide (GIP) act via specific G-protein-coupled receptors to potentiate insulin secretion from pancreatic β-cells in a glucose-dependent manner
Search for other papers by Bernard Khoo in
Google Scholar
PubMed
Search for other papers by Tricia Mei-Mei Tan in
Google Scholar
PubMed
gut hormone path-finder Glucagon-like peptide 1 (GLP-1) is the most extensively studied gut hormone with translational and clinical evidence for its efficacy ( Holst 2007 ). It is an alternatively processed product of the proglucagon peptide
